Showing 1551-1560 of 1692 results for "".
- Lasmiditan Treatment Provides Pain Freedom At 2 Hours in at Least 2 of 3 Migraine Attacks in New Phase 3 Studyhttps://practicalneurology.com/news/lasmiditan-treatment-provides-pain-freedom-at-2-hours-in-at-least-2-of-3-migraine-attacks-in-new-phase-3-study/2469397/In the phase 3 CENTURION study, participants treated with lasmiditan (Reyvow; Eli Lilly, Indianapolis, IN) for migraine attacks, doses of 100 mg or 200 mg, had 3.8 and 7.2 times greater odds of achieving pain freedom at 2 hours post treatment compared with placebo in at least 2 out of 3 attacks.&
- Investigation of Foralumab for Alzheimer Disease Treatment Will Continue to Phase 2https://practicalneurology.com/news/investigation-of-foralumab-for-alzheimer-disease-treatment-will-continue-to-phase-2/2469286/Nasally administered foralumab (Tiziana Life Sciences, New York, NY) has showed delays in disease processes underlying the progression of Alzheimer disease (AD) in animal models . Based on those results, the investigation of foralumab for AD will continue to phase 2 clinical trials. Foralum
- Shine Forward with Dravet, Support Resource for Parents of Children Living with Dravet Syndrome Launchedhttps://practicalneurology.com/news/shine-forward-with-dravet-support-resource-for-parents-of-children-living-with-dravet-syndrome-launched/2469264/A new resource for parents of children with Dravet syndrome (DS), Shine Forward with Dravethas been launched by pharmaceutical company Zogenix (Emeryville, CA). The website includes a unique set of online tips, tools, and advice from families and is designed to inspire deeper connections between
- Once-Nightly Extended Release Formulation of Sodium Oxybate Shows Efficacy for Excessive Daytime Sleepiness and Cataplexyhttps://practicalneurology.com/news/once-nightly-extended-release-formulation-of-sodium-oxybate-shows-efficacy-for-excessive-daytime-sleepiness-and-cataplexy/2469241/A phase 3 clinical trial shows that an investigational extended release formulation of sodium oxybate (FT218; Avadel Pharmaceuticals, Dublin, Ireland) increased wakefulness and decreased cataplexy. This unique formulation of sodium oxybate uses a micropump technology to allow for once nightly dos
- Ubrogepant Provides Freedom from Pain for Acute Treatment of Migraineshttps://practicalneurology.com/news/ubrogepant-treatment-of-migraine-provides-freedom-from-pain-for-acute-treatment-of-migraine/2469102/The results from the phase 3 ACHIEVE I trial (NCT02828020) evaluated the efficacy, safety, and tolerability of ubrogepant (Allergan; Madison, NJ). Acute treatment of migraine with ubrogepant provided higher rates of pain freedom and fre
- Generic Fingolimod for Relapsing Forms of Multiple Sclerosis Approved by the FDAhttps://practicalneurology.com/news/generic-fingolimod-for-relapsing-forms-of-multiple-sclerosis-approved-by-the-fda/2469094/The Food and Drug Administration (FDA) has approved 3 applications for the first generics of fingolimod (Gilenya; Novartis AG, Basel, Switzerland) for treating relapsing forms of multiple sclerosis (MS) in adult patients. Fingolimod is a sphingosine 1-phosphate receptor modulator indica
- Edaravone Oral Formulation Being Tested in Phase 3 Trial for ALShttps://practicalneurology.com/news/edaravone-oral-formulation-being-tested-in-phase-3-trial-for-als/2469086/The first participant has been enrolled in a global phase 3 study (NCT04165824) of an oral suspension formulation of edaravone (Radicava; Mitsubishi Tanabe Pharma, Jersey City, NJ) for potential treatment of amyotrophic lateral scleros
- Results for Cryopreserved Gene Therapy Formulation for Treatment of Early-Onset Metachromatic Leukodystrophyhttps://practicalneurology.com/news/results-for-cryopreserved-gene-therapy-formulation-for-treatment-of-early-onset-metachromatic-leukodyphy/2469057/In initial results from the A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (NCT03392987) of a cryopreserved gene therapy formulation (OTL-200: Orchard Therapeutics, Boston, MA)
- Perampanel Monotherapy May Provide Seizure Freedomhttps://practicalneurology.com/news/perampanel-monotherapy-may-provide-seizure-freedom/2468937/In a phase 3 study, perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) used as monotherapy for new-onset or untreated partial-onset seizures (POS) provided seizure freedom for 63% (46/73) of people treated (95% CI: 50.9–74.0). In an open-label descriptive study (
- Feasibility of Leqembi Treatment Supported by Real-World Data from Specialty Memory Clinichttps://practicalneurology.com/news/feasibility-of-leqembi-treatment-supported-by-real-world-data-from-specialty-memory-clinic/2474841/One specialty memory clinic found that it was feasible and manageable to treat people with early symptomatic Alzheimer disease (AD) using Leqembi (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA), according to results of a retrospective analysis published in JAMA Neurology. Th